122 related articles for article (PubMed ID: 12713607)
1. Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback.
Monjanel-Mouterde S; Ciccolini J; Bagarry D; Zonta-David M; Duffaud F; Favre R; Durand A
J Clin Pharm Ther; 2003 Apr; 28(2):109-16. PubMed ID: 12713607
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
[TBL] [Abstract][Full Text] [Related]
3. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
[TBL] [Abstract][Full Text] [Related]
6. Adaptive control methods for the dose individualisation of anticancer agents.
Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program.
Nagai N; Ogata H; Wada Y; Tsujino D; Someya K; Ohno T; Masuhara K; Tanaka Y; Takahashi H; Nagai H; Kato K; Koshiba Y; Igarashi T; Yokoyama A; Kinameri K; Kato T; Kurita Y
J Clin Pharmacol; 1998 Nov; 38(11):1025-34. PubMed ID: 9824784
[TBL] [Abstract][Full Text] [Related]
8. [Validation of a new interactive software monitoring a controlled-flow infusion pump for cisplatin dosage regimen adjustment].
Cupissol D; Brès J; Gestin-Boyer C; Nouguier-Soulé J; Vian L; Tep A; Nouguier J
Bull Cancer; 1996 Aug; 83(8):664-76. PubMed ID: 8869047
[TBL] [Abstract][Full Text] [Related]
9. [Population pharmacokinetics applied to optimising cisplatin doses in cancer patients].
Ramón-López A; Escudero-Ortiz V; Carbonell V; Pérez-Ruixo JJ; Valenzuela B
Farm Hosp; 2012; 36(5):392-402. PubMed ID: 22402361
[TBL] [Abstract][Full Text] [Related]
10. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.
Rousseau A; Marquet P
Fundam Clin Pharmacol; 2002 Aug; 16(4):253-62. PubMed ID: 12570013
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.
Urien S; Brain E; Bugat R; Pivot X; Lochon I; Van ML; Vauzelle F; Lokiec F
Cancer Chemother Pharmacol; 2005 Jan; 55(1):55-60. PubMed ID: 15258698
[TBL] [Abstract][Full Text] [Related]
12. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of etoposide: application to therapeutic drug monitoring.
Ciccolini J; Monjanel-Mouterde S; Bun SS; Blanc C; Duffaud F; Favre R; Durand A
Ther Drug Monit; 2002 Dec; 24(6):709-14. PubMed ID: 12451286
[TBL] [Abstract][Full Text] [Related]
14. Platinum pharmacokinetics in sulphur-crested cockatoos (Cacatua galerita) following single-dose cisplatin infusion.
Filippich LJ; Bucher AM; Charles BG
Aust Vet J; 2000 Jun; 78(6):406-11. PubMed ID: 10920780
[TBL] [Abstract][Full Text] [Related]
15. Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.
Baille P; Bruno R; Schellens JH; Webster LK; Millward M; Verweij J; Montay G
Clin Cancer Res; 1997 Sep; 3(9):1535-8. PubMed ID: 9815840
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of cisplatin in adult cancer patients.
de Jongh FE; Gallo JM; Shen M; Verweij J; Sparreboom A
Cancer Chemother Pharmacol; 2004 Aug; 54(2):105-12. PubMed ID: 15127229
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Felici A; Loos WJ; Verweij J; Cirillo I; de Bruijn P; Nooter K; Mathijssen RH; de Jonge MJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):673-80. PubMed ID: 16544143
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum.
Hanada K; Nishijima K; Ogata H; Atagi S; Kawahara M
Jpn J Clin Oncol; 2001 May; 31(5):179-84. PubMed ID: 11450990
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.
Loh GW; Ting LS; Ensom MH
Clin Pharmacokinet; 2007; 46(6):471-94. PubMed ID: 17518507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]